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Background: Despite recognised treatment strategies, mortality associated with tuberculosis (TB) remains significant.
Risk factors for death during TB treatment have been described but the complex relationship between TB and HIV has
not been fully understood.
Methods: A retrospective analysis of all deaths occurring during TB treatment in Cape Town, South Africa between
2009 and 2012 were done to investigate risk factors associated with this outcome. The main risk factor was HIV status
at the start of treatment and its interaction with age, sex and other risk factors were evaluated using a binomial
regression model and thus relative risks (RR) are reported.
Results: Overall in the 93,133 cases included in the study 4619 deaths (5 %) were recorded. Across all age groups
HIV-positive patients were more than twice as likely to die as HIV-negative patients, RR = 2.19 (95 % CI: 2.03–2.37).
However in an age specific analysis HIV-positive patients 15–24 and 25–34 years old were at an even higher risk of
dying than HIV-negative patients, RR = 4.82 and RR = 3.76 respectively. Gender also modified the effect of HIV- with
positive women having a higher risk of death than positive men, RR = 2.74 and RR = 1.94 respectively.
Conclusion: HIV carries an increased risk of death in this study but specific high-risk groups pertaining to the impact of
HIV are identified. Innovative strategies to manage these high risk groups may contribute to reduction in HIV-associated
death in TB patients.
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Despite effective chemotherapy, tuberculosis (TB)-asso-
ciated mortality remains high and is the leading cause of
death in South Africa accounting for 11 % of all South
African deaths [1]. The World Health Organization
(WHO) estimated 1.4 million TB deaths in 2012, of which
430 000 were among Human Immunodeficiency Virus
(HIV)-positive individuals [2].
Waitt and Squire identified 62 studies in a systematic
review to explore risk factors for death in patients
started on TB treatment [3]. Retrospective and prospective* Correspondence: james.seddon@imperial.ac.uk
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were included. This review revealed two distinct epidemics
with separate risk factors for death. Risk factors for death
while on TB treatment in high HIV/TB regions include
HIV positivity, atypical chest radiographic features, spu-
tum smear-negative disease, advanced immunosuppres-
sion and malnutrition and in low HIV/TB burden regions
include increased age, typical features of severe TB on
chest radiograph, smear positivity and socio-demographic
disadvantage (alcohol, injectable drug use and homeless-
ness). It is possible, even likely, that these two epidemics
co-exist within populations. HIV positivity and severe im-
munosuppression are risk factors for the development of
TB disease and for death on TB treatment [4, 5]. Combin-
ation antiretroviral therapy (cART) offers protection bothrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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TB treatment [7]. However, the picture is more compli-
cated and it is still unclear why some patients (both HIV-
positive and -negative) die following the diagnosis of TB
and exactly which HIV-positive patients are at the greatest
risk.
Understanding factors associated with death while on
TB treatment permits the development of strategies to
strengthen the TB control programme. We aimed to de-
termine risk factors for death in adult patients on TB
treatment under programmatic conditions in Cape Town
and describe these factors in relation to HIV infection.
Methods
Setting
This retrospective cohort study was conducted in the
City of Cape Town district (population estimate of 3.7
million in 2011 [1]), located in the Western Cape of
South Africa. There are 160 primary health care (PHC)
facilities (clinics, mobile/satellite facilities and commu-
nity health centres) in the district which offer free TB
testing, of which 103 offer outpatient TB treatment. In
addition there are 15 hospitals where inpatients can be
started on treatment and then referred to PHC facilities
for continuation of treatment. These PHC TB treatment
facilities are distributed across the city and organised
into eight sub-districts.
The City of Cape Town district reported a decrease in
reported TB cases per population from 877/100,000 in
2009 to 663/100,000 in 2013 with a cure rate of 83 %
among all patients who started TB treatment in 2013
[8]. Laboratory diagnosis of TB in Cape Town utilised
smear microscopy, culture and line probe assay until
August 2011, after which the GeneXpert MTB/RIF assay
(Xpert; Cepheid, Sunnyvale, CA) was progressively intro-
duced for the testing of all patients with presumptive
TB. TB treatment regimens were in accordance with
international standards: combination chemotherapy with
rifampicin, isoniazid, ethambutol and pyrazinamide; an
initial intensive phase followed by a continuation phase.
HIV testing was performed using rapid testing according
to National guidelines [9].
Study population and data sources
All TB patients treated for drug-susceptible TB are re-
corded in a paper-based register at their PHC treatment
facility. If started on treatment in hospital, they should
still be recorded at their local PHC facility. These paper
registers are captured at a sub-district level into an elec-
tronic database, (ETR.net) which includes patient-specific
details (age, gender, address), disease-specific details (site
of disease, sputum smear results, treatment regimen, HIV
status and CD4 count) and TB outcome (treatment com-
pleted, cured, defaulted, died, failed). All adults (≥15 years)treated for drug-susceptible TB in the City of Cape Town
District, and recorded in the ETR.net, were included if
started on treatment between 1 January 2009 and 30 June
2012. This included adults with any form of TB but ex-
cluded cases with confirmed drug-resistant TB.
Definitions
New cases were those recorded in ETR.net as not having
been treated previously for TB or who had received less
than four weeks of TB treatment. Retreatment cases
were those recorded in ETR.net as having received more
than four weeks of TB treatment, regardless of time
since the previous episode or outcome. Patients were re-
corded as sputum smear-positive if a sputum specimen,
taken prior to TB treatment, was noted to be 1+, 2+ or
3 + for acid fast bacilli on microscopy. Patients were con-
sidered HIV-positive if, in ETR.net, they had a positive
HIV status recorded, were recorded to be on antiretro-
viral medication, if they had a recorded CD4 result or if
they were on co-trimoxazole. TB treatment outcomes
were those recorded in the ETR.net.
Data collection
Data for all adult TB cases were exported from ETR.net
per sub-district and combined into a single database.
Personal identifiers including first name, surname and
date of birth were included for matching and exclusion
of duplicate entries, and subsequently removed. The
final database contained no personal identifiers. The data
was analysed using Stata 12.1 (StataCorp. 2011. Stata Stat-
istical Software: Release 12. College Station, TX: StataCorp
LP). Ethical approval and a waiver of individual informed
consent were received from the Stellenbosch University
Health Research Ethics Committee (S12/01/018) and per-
mission was obtained from the City of Cape Town Health
Directorate.
Statistical analysis
The proportion of patients dying was displayed by HIV
status for each of the demographic and clinical variables.
All variables were analysed categorically using frequen-
cies and percentages. Age was stratified: 15–24 years,
25–34 years, 35–44 years, 45–54 years, 55–64 years and
65+ years and CD4 count was categorized: <50 cells/
mm3, 51–200 cells/mm3, 201–350 cells/mm3, 351–500
cells/mm3 and >500 cells/mm3. Kaplan Meier curves
were generated for time to death by HIV status. Time to
death was calculated as the time in days between the TB
treatment initiation date and the date of death docu-
mented in the ETR.net. Patients were censored from
analysis either 180 days after TB initiation or at the time
of their death, whichever event occurred first. A bino-
mial log-linear regression model was used to determine
which demographic and clinical characteristics were
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fidence intervals (CIs) were reported. Two- and three-
way interactions between HIV and demographic and
clinical characteristics were assessed and, if any interac-
tions were statistically significant, the modified HIV
mortality RRs were reported. A two-way interaction be-
tween CD4 count and age was assessed and the modified
mortality RRs were reported. Standard errors for both
binomial log-linear regression models were adjusted to
account for any possible health care facility clustering.
Results
All TB cases
Between 1 January 2009 and 30 June 2012, 107 401 TB
cases were recorded in the ETR.net (Fig. 1). Of these,
14 259 were children less than 15 years of age, seven
were cases of MDR-TB and two were enrolled at a mili-
tary clinic; these were all excluded from further analysis.
Demographic details as well as baseline TB data were
available for analysis in the 93 133 TB cases. Sputum
smear results were recorded in 89.9 % of all cases; HIV
status could be determined in 96.9 % of TB cases and of
those HIV-positive, 94.6 % had a CD4 count recorded.
Of the 93 133 TB cases, 51 322 (55.1 %) were male,
47 332 (50.8 %) were HIV-positive and 4619 (5.0 %)
died (Table 1).
TB cases who were HIV-positive (RR: 2.19; 95 % CI:
2.03, 2.37) or had an unknown HIV status (RR: 1.86;
95 % CI 1.57, 2.21) were at an increased risk of death
(Table 2). Cases over 65 years were at higher risk of
death than younger cases (RR: 9.16; 95 % CI 7.79, 10.80),
those with extrapulmonary TB had a greater risk ofFig. 1 Schematic diagram of study population selected for analysisdeath than those with pulmonary TB (RR: 1.14; 95 % CI:
1.04, 1.26) while cases with sputum smear-positive TB
had a lower risk (RR: 0.88; 95 % CI: 0.82, 0.94) than those
with sputum smear-negative TB. The risk of death was
marginally higher in men than women (RR: 1.06; 95 % CI:
1.01, 1.12) and higher in retreatment cases (RR: 1.33;
95 % CI: 1.23, 1.45) (Table 2). The death rate fell between
2009 and 2012 (RR: 0.83; 95 % CI: 0.74, 0.93). Figure 2 dis-
plays the Kaplan-Meier survival curves showing the time
to death by HIV status. Patients with unknown HIV status
had more early deaths but the curve adopted a similar
shape to the HIV-negative population after 90 days.
Impact of HIV
For 15–24 year olds, HIV-positive patients were nearly
five times more likely to die than HIV-negative patients
(RR: 4.82; 95 % CI: 3.88, 5.99), whereas for patients 55–
64 years, HIV-positive patients were only marginally
more likely to die (RR: 1.26; 95 % CI: 1.06, 1.50; Table 3
and Fig. 3). For individuals with sputum smear-positive
disease, those with HIV were more likely to die than
those without HIV (RR: 2.82; 95 % CI: 2.58, 3.07). This
is greater than the increased risk in HIV-positive com-
pared to HIV-negative patients with smear-negative dis-
ease (RR: 1.85; 95 % CI: 1.68, 2.04). HIV-positive women
were more likely to die than HIV-negative women (RR:
2.74; 95 % CI: 2.43, 3.08). The effect of HIV was less pro-
nounced in men (RR: 1.94; 95 % CI: 1.77, 2.11; Table 3).
In sub-group analysis, HIV-positive patients with
CD4 count <50 cells/mm3 had high risk of death com-
pared to HIV-negative patients (RR: 3.83; 95 % CI: 3.48,
4.21). HIV-positive patients with CD4 count above
Table 1 Demographic and clinical characteristics for adult TB cases, stratified by HIV status and death (n = 93 133)
HIV-positive HIV-negative HIV status unknown Total died
(n = 4619)Alive Died Alive Died Alive Dead
(n = 44 315) (n = 3017) (n = 41 548) (n = 1408) (n = 2651) (n = 194)
Mean age in years at registration (SD) 34.9 (9.1) 37.9 (10.3) 36.0 (14.4) 51.1 (15.8) 36.0 (14.5) 50.1 (17.4) 42.4 (14.0)
Age in years at registration
15–24 (%) 4531 (95.6) 208 (4.4) 11 358 (99.1) 98 (0.9) 597 (97.5) 15 (2.5) 321 (1.9)
25–34 (%) 19 064 (94.8) 1044 (5.2) 10 292 (98.7) 134 (1.3) 857 (96.6) 30 (3.4) 1208 (3.8)
35–44 (%) 14 236 (93.2) 1035 (6.8) 7917 (97.6) 194 (2.4) 534 (94.5) 31 (5.5) 1260 (5.3)
45–54 (%) 5096 (90.8) 519 (9.2) 7122 (95.0) 377 (5.0) 343 (90.0) 38 (10.0) 934 (6.9)
55–64 (%) 1220 (88.0) 166 (12.0) 3383 (91.1) 329 (8.9) 182 (84.7) 33 (15.3) 528 (9.9)
> 64 (%) 168 (78.9) 45 (21.1) 1476 (84.2) 276 (15.8) 138 (74.6) 47 (25.4) 368 (17.1)
Gender
Male (%) 21 037 (93.3) 1464 (6.8) 26 009 (96.3) 988 (3.7) 1709 (93.7) 115 (6.3) 2567 (5.1)
Female (%) 24 078 (93.9) 1553 (6.1) 15 539 (97.4) 420 (2.6) 942 (92.3) 79 (7.7) 2052 (4.8)
Median CD4 count for HIV-positive patients [IQR] 167 [77–298] 93 [37–191]
< 50 cells/mm3 (%) 7039 (89.0) 872 (11.0)
51–200 cells/mm3 (%) 17 671 (93.6) 1209 (6.4)
201–350 cells/mm3 (%) 9895 (96.0) 407 (4.0)
351–500 cells/mm3 (%) 4736 (96.9) 154 (3.1)
> 500 cells/mm3 (%) 3171 (97.2) 91 (2.8)
Missing 1803 (86.4) 284 (13.6)
Baseline sputum smear
Negative (%) 24 855 (93.7) 1591 (6.3) 13 590 (95.6) 628 (4.4) 884 (92.8) 69 (7.2) 2288 (5.6)
Positive (%) 14 572 (94.0) 938 (6.0) 25 392 (97.6) 625 (2.4) 1488 (95.3) 74 (4.7) 1637 (3.8)
No smear (%) 5888 (92.3) 488 (7.7) 2566 (94.3) 155 (5.7) 279 (84.5) 51 (15.5) 694 (7.4)
Disease classification
PTB (%) 33 664 (93.9) 2205 (6.1) 37 132 (96.9) 1174 (3.1) 2293 (93.7) 155 (6.3) 3534 (4.6)
EPTB (%) 9410 (93.0) 705 (7.0) 4056 (95.1) 208 (4.9) 329 (90.6) 34 (9.4) 947 (6.4)
Both (%) 1241 (92.1) 107 (7.9) 360 (93.3) 26 (6.7) 29 (85.3) 5 (14.7) 138 (7.8)
Category
Retreatment (%) 13 738 (92.2) 1167 (7.8) 11 520 (95.2) 582 (4.8) 637 (91.4) 60 (8.6) 1809 (6.5)
New (%) 30 577 (94.3) 1850 (5.7) 30 028 (97.3) 826 (2.7) 2014 (93.8) 134 (6.2) 2810 (4.3)
Registration year
2009 12 771 (93.0) 965 (7.0) 11 506 (96.3) 436 (3.7) 1262 (93.4) 89 (6.6) 1490 (5.5)
2010 12 971 (93.6) 893 (6.4) 12 147 (96.7) 414 (3.3) 710 (93.7) 48 (6.3) 1355 (5.0)
2011 12 739 (94.2) 787 (5.8) 11 929 (97.0) 365 (3.0) 453 (91.5) 42 (8.5) 1194 (4.5)
2012 5834 (94.0) 372 (6.0) 5966 (96.9) 193 (3.1) 226 (93.8) 15 (6.2) 580 (4.6)
SD standard deviation, IQR interquartile range, TB tuberculosis, PTB pulmonary TB, EPTB extra-pulmonary TB
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HIV-negative patients (RR: 1.07; 95 % CI: 0.93, 1.23;
Table 4). In further sub-group analysis of HIV-positive
TB cases by CD4 count and age, individuals 15–24
years with a CD4 count <50 cells/mm3 had high risk of
death, compared to HIV-negative cases (RR: 10.29;
95 % CI: 7.66, 13.82), while older patients (55–64 years)
with a CD4 count of <50 cells/mm3 had only amarginally increased risk (RR 2.46; 95 % CI: 1.88, 3.22;
Table 4 and Fig. 4).
Discussion
In this retrospective analysis we have shown HIV-
positive and HIV-unknown patients with TB have an in-
creased risk of death during TB treatment. We have
demonstrated that older age contributes to an increase
Table 2 Estimated RR of TB mortality from a main effects
model using binomial log-linear regression (n = 93 133)
RR (95 % CI)
HIV status
Negative Ref
Positive 2.19 (2.03–2.37)
Unknown 1.86 (1.57–2.21)
Age group
15–24 years Ref
25–34 years 1.44 (1.28–1.63)
35–44 years 1.93 (1.70–2.18)
45–54 years 2.95 (2.64–3.30)
55–64 years 4.75 (4.12–5.48)
65+ years 9.16 (7.79–10.78)
Baseline smear
Negative Ref
Positive 0.88 (0.82–0.94)
No smear 1.25 (1.13–1.37)
Disease classification
PTB Ref
EPTB 1.14 (1.04–1.26)
Both 1.30 (1.10–1.55)
Gender
Female Ref
Male 1.06 (1.01–1.12)
Type of treatment
New Ref
Retreatment 1.34 (1.24–1.44)
Year
2009 Ref
2010 0.92 (0.86–0.99)
2011 0.83 (0.76–0.90)
2012a 0.83 (0.74–0.93)
RR relative risk, CI confidence interval, TB tuberculosis, PTB pulmonary TB, EPTB
extra-pulmonary TB
aOnly the first 6 months of 2012 were included in this analysis
Fig. 2 Kaplan-Meier survival curves depicting time to death according
to HIV
Table 3 Crude and specific relative risk estimates for impact of
HIV, comparing HIV-positive and negative patients
RR (95 % CI) p-value
HIV Status
HIV-positive 2.19 (2.03–2.37) <0.001
Age group
15–24 years 4.82 (3.88–5.99) <0.001
25–34 years 3.76 (3.12–4.53) <0.001
35–44 years 2.64 (2.28–3.06) <0.001
45–54 years 1.75 (1.53–1.99) <0.001
55–64 years 1.26 (1.06–1.50) 0.008
65+ years 1.23 (0.91–1.66) 0.169
Baseline smear
Negative 1.85 (1.68–2.04) <0.001
Positive 2.82 (2.58–3.07) <0.001
No smear 1.77 (1.46–2.14) <0.001
Gender
Female 2.74 (2.43–3.08) <0.001
Male 1.94 (1.77–2.11) <0.001
RR relative risk, CI confidence interval
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finding consistent with previous studies [10]. This may
be due to concomitant pathology, less physical reserves
or it may reflect an increasing frequency of non-TB
causes of death. We have showed that the impact of
HIV was greater in younger, as opposed to older, pa-
tients, with severe immunosuppression also having a
greater impact on death in younger patients. These dif-
ferences may reflect a combination of HIV greatly
impacting on mortality in younger people combined
with limited impact in those older. Older people fre-
quently have additional pathologies that might affect
their outcome for TB, in addition to HIV. Youngerpeople, however, rarely have other conditions. Younger
people may delay seeking care for their HIV more than
older people which might impact on survival. Another
possibility is that HIV-positive individuals who survive
to older age are likely to have better controlled HIV
and be taking cART conscientiously. The effect of gen-
der has been described in a previous small study [11]
and we have shown that men have a higher proportion
of deaths on TB treatment than women regardless of
HIV infection. However, we also demonstrated that
the effect of HIV on death during TB treatment was
greater in females; the reasons for this need further
investigation.
Fig. 3 Relative risk estimates for death by age groups, comparing
HIV-positive TB cases with HIV-negative cases
Table 4 Adjusted risk of death for HIV-positive patients by CD4
count compared to HIV-negative (n = 88 201) (excludes HIV
unknown and CD4 missing)
RR (95 % CI) p-value
All ages by CD4 count
< 50 cells/mm3 3.83 (3.48–4.21) <0.001
51–200 cells/mm3 2.21 (2.02–2.43) <0.001
201–350 cells/mm3 1.39 (1.25–1.55) <0.001
> 350 cells/mm3 1.07 (0.93–1.23) 0.321
Age 15–24 years by CD4 count
< 50 cells/mm3 10.29 (7.66–13.8) <0.001
51–200 cells/mm3 5.00 (3.74–6.68) <0.001
201–350 cells/mm3 2.70 (1.84–3.96) <0.001
> 350 cells/mm3 2.32 (1.59–3.39) <0.001
Age 25–34 years by CD4 count
< 50 cells/mm3 6.56 (5.41–7.95) <0.001
51–200 cells/mm3 3.69 (3.05–4.47) <0.001
201–350 cells/mm3 2.18 (1.73–2.74) <0.001
> 350 cells/mm3 1.54 (1.15–2.06) 0.003
Age 35–44 years by CD4 count
< 50 cells/mm3 4.18 (3.49–5.00) <0.001
51–200 cells/mm3 2.67 (2.25–3.17) <0.001
201–350 cells/mm3 1.74 (1.43–2.11) <0.001
> 350 cells/mm3 1.43 (1.11–1.83) 0.005
Age 45–54 years by CD4 count
< 50 cells/mm3 3.30 (2.75–3.96) <0.001
51–200 cells/mm3 1.78 (1.55–2.05) <0.001
201–350 cells/mm3 1.15 (0.91–1.45) 0.239
> 350 cells/mm3 0.72 (0.49–1.06) 0.099
Age 55–64 years by CD4 count
< 50 cells/mm3 2.46 (1.88–3.22) <0.001
51–200 cells/mm3 1.09 (0.78–1.51) 0.621
201–350 cells/mm3 0.84 (0.59–1.19) 0.329
> 350 cells/mm3 0.95 (0.63–1.43) 0.811
Age 65+ years by CD4 count
< 50 cells/mm3 1.70 (1.03–2.80) 0.039
51–200 cells/mm3 1.45 (0.93–2.26) 0.101
201–350 cells/mm3 0.97 (0.58–1.61) 0.892
> 350 cells/mm3 0.55 (0.20–1.51) 0.247
RR relative risk, CI confidence interval
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smear status and site of TB is also complex; previous
studies have shown a relationship between sputum
smear-negative pulmonary disease and mortality, as well
as extra-pulmonary TB and mortality [12]. However in
our study, the impact of HIV on death was greater in
those who had smear-positive disease as opposed to
smear-negative. Again, the reasons are unclear. Patients
with unknown HIV status comprised a very small pro-
portion (3.1 %) of the patients on TB treatment, reflect-
ing excellent uptake of voluntary testing for HIV in this
high risk population. Our Kaplan-Meier curve shows
that some of those with unknown HIV status die rapidly,
after which the curve assumes the trajectory of the HIV-
negative cohort.
In an attempt to understand these interactions, it is
important to consider factors which impact on mortality
in patients treated for TB. Alcohol is strongly associated
with the development of TB [13] and also with poor out-
come on treatment [14, 15]. This is significant in Cape
Town where there is a high rate of alcohol dependence
and a complex interplay exists between the biomedical
and social aspects of TB, HIV and alcohol. This may im-
pact on the age and gender interactions with HIV and
death. Smoking cigarettes and using solid fuels to cook
and heat homes is also associated with TB, both the risk
of developing TB as well as dying on treatment [16, 17].
This is also relevant in Cape Town where many, espe-
cially the young, smoke cigarettes, some smoke drugs
and many still use solid fuels for cooking and heating.
Diabetes [18, 19], malnutrition [11, 20–22] and mental
health [23, 24] all affect both HIV and TB. These condi-
tions are associated with or pre-dispose to TB and lead
to poor outcomes. However, all three also have a rela-
tionship with HIV which can affect the endocrine system
of individuals, as well as their nutrition and their psy-
chological well-being. Patients with drug-resistant strainsof M. tuberculosis have poorer outcomes than those with
drug-susceptible strains [25], and although patients with
known drug-resistant TB were not included in this ana-
lysis, it is likely that some cases would have been re-
corded in ETR.net. Although there does not appear to
be a relationship between HIV and the occurrence of TB
drug resistance [26], mortality is higher in HIV-positive
Fig. 4 Relative risk for death between HIV-negative and-positive
patients at different CD4 counts, stratified by age
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negative patients with drug-resistant forms of disease [27].
Within the group of HIV-positive patients, there are
additional risk factors for death. The degree of immuno-
suppression is associated with both the development of
TB as well as poor outcomes if TB develops [5]. Not be-
ing on cART at the start of TB treatment, or not starting
cART following the initiation of TB treatment, is associ-
ated with death [6]. Even for those on cART, with full
virological suppression, a failure to develop immuno-
logical recovery has been shown to be associated with
death [28]. The presence of opportunistic infections, in
addition to TB, has also been shown to influence mortal-
ity [29]; co-infection with cryptococcus [30] and human
T cell lymphotropic virus [31] has been associated with
death in HIV-positive patients treated for TB. These fac-
tors may all contribute to interaction between age, gen-
der, HIV and outcome. Studies from the pre-cART era
[32], as well as studies following the introduction of
cART [33], demonstrate a survival advantage in patients
who had been given co-trimoxazole, suggesting the pre-
vention of deaths from causes other than TB.
This study is one of the largest described cohorts of
adults treated for TB. From this dataset we are able to
tease out some of the intricacies of the relationship be-
tween HIV and TB. However, as with any retrospective
study of routine data, limitations exist. First, missing
data did occur. Although the dataset was relatively
complete, the documentation of cART uptake was rela-
tively poor and was not included in any descriptive out-
puts or any models. Although the number of patients
with unknown HIV status was relatively small, the pro-
portion was greater for older age-groups as compared to
younger age-groups. It is possible that this may have in-
fluenced the perceived impact of HIV on death in differ-
ent age-groups. There was some uncertainty around the
accuracy of the recorded date of death and aside fromthe Kaplan Meier curve, we did not use this in our ana-
lysis. Some important variables such as smoking, alcohol
use, opportunistic infections, body mass index etc. are
not routinely recorded in ETR.net and require prospect-
ive studies for evaluation. The study defined death as a
TB case dying before the end of treatment regardless of
cause. It does not reflect the true mortality associated
with TB, as it includes death due to accidents or co-
morbidities. In HIV-positive populations, a significant
proportion of deaths on TB treatment are not caused by
TB [34, 35]. It also does not account for deaths occur-
ring prior to treatment initiation, deaths in those who
have defaulted or death occurring after treatment. As
the study took place in one location, it may not be pos-
sible to generalise these findings to other settings.
While the study period is restricted to 42 months, a
declining trend in annual mortality is observed and
some of this effect may be due to a number of changes
to cART policy in South Africa in recent years, with pa-
tients initiated onto cART at higher CD4 counts [36]. It
is important that this trend continues to be measured
and future studies should evaluate this over a longer
duration.
More extensive HIV testing is required in the commu-
nity so that HIV-positive individuals are identified early
and placed on cART prior to developing TB. While mor-
tality in the younger population is much lower than the
older population, this study supports the implementa-
tion of HIV prevention interventions. Death among
younger TB patients could be prevented as the majority
of younger TB patients would not have died without
HIV. Furthermore, the increased risk of death associated
with HIV in patients with TB could be mitigated by
knowledge of HIV status and early ART especially for
those with low CD4 counts. A recent study demon-
strated significant advantages associated with widespread
implementation of WHO standards with improved out-
comes when HIV-positive patients were started on ART
early [37]. Finally, ongoing improvements in data record-
ing and reporting will allow us to continue to assess the
epidemic as it evolves.Abbrevaitions
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